The Peptide FDA Status Tracker: What Changed in 2025–2026

Overview: How FDA Regulates Peptides

The FDA regulates peptides in two primary ways: as approved drugs (with confirmed safety/efficacy for specific indications) or as unapproved new drugs (when marketed for unapproved uses or without a valid NDA/BLA). Peptides also fall under the Dietary Supplement Health and Education Act (DSHEA) when marketed as supplements — though the line is contested.

The FDA's Office of Regulatory Affairs (ORA) and Center for Drug Evaluation and Research (CDER) jointly determine enforcement priorities. The agency does not typically comment on enforcement timelines in advance.

For a complete picture, consult the FDA's drug compounding guidance page and the FDA drug shortage database.

BPC-157: Research Compound, Not Approved

BPC-157 (body protection compound-157) remains an investigational peptide with no FDA-approved therapeutic indication. It has not undergone phase 3 clinical trials for any condition. All available data comes from preclinical (rodent) studies exploring its effect on wound healing, angiogenesis, and GI protection.

In 2024–2025, FDA enforcement actions targeted BPC-157 in two key ways:

• Import alerts on BPC-157 raw powder shipments from certain international suppliers
• Warning letters to compounding pharmacies marketing BPC-157 as a standardized product
• Import alerts on BPC-157 finished dosage forms from specific overseas facilities

BPC-157 is not scheduled under the Controlled Substances Act. However, marketing it as a treatment for specific conditions (e.g., "for tendon repair") without FDA approval constitutes a violation of the Federal Food, Drug, and Cosmetic Act.

A database of FDA enforcement letters related to peptides is maintained by the U.S. Attorney's Office for reference. We do not link to specific enforcement actions as these may change; consult the FDA warning letter database for current records.

FDA-Approved Peptides: Semaglutide, Tirzepatide, Retatrutide

Several peptides are FDA-approved drugs with established safety profiles and labeled indications:

These are fully legal, prescribed medications. They have FDA-approved labeling, manufacturing standards, and post-market surveillance. If you're using these under a valid prescription, the regulatory risk is minimal to none.

Research Peptides: A Gray Zone That's Getting Grayer

The compounds in the gray zone — BPC-157, TB-500, CJC-1295, Ipamorelin, PT-141 — are not scheduled substances, but they are also not approved drugs. The FDA's position is consistent: marketing an investigational peptide as a treatment for a specific condition requires approval.

What changed in 2025–2026:

• Compounding Clarity: FDA finalized guidance clarifying that bulk drug substance compounding for office stock is only permitted when the substance is on the 503A bulks list or when there is a clinical need not met by approved products. BPC-157 is not on this list.
• Import Alert Expansion: FDA expanded import screening for peptide raw materials from additional countries. This has affected some clinic supply chains but has not eliminated personal use imports.
• State-Level Action: Several state boards of pharmacy have issued notices to clinics marketing peptide protocols for unapproved uses. This is not federal enforcement but creates parallel risk.

What This Means for Users

If you're using FDA-approved peptides (semaglutide, tirzepatide) with a valid prescription: no change to your status. You're operating within the system.

If you're using research peptides: the federal risk is low for personal use, but the landscape is tightening. Clinic-level enforcement is increasing. Supply chains are becoming less reliable. Quality control is inconsistent because these compounds are not subject to cGMP manufacturing requirements for approved drugs.

The practical advice:

• If you are using a research peptide for a specific medical indication, work with a licensed clinician who is actively monitoring your labs and can document medical necessity.
• Track everything. If FDA enforcement ever targets a specific user, documentation of medical oversight and clinical rationale is the primary defensibility mechanism.
• Watch the approved compound pipeline. If retatrutide or another triple agonist gets approved for obesity, it may replace off-label use of research peptides for weight management.